1. Academic Validation
  2. Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs

Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs

  • Br J Clin Pharmacol. 2018 May;84(5):952-960. doi: 10.1111/bcp.13517.
Maiko Nomoto 1 Cynthia A Zamora 2 Edgar Schuck 3 Peter Boyd 4 Min-Kun Chang 3 Jagadeesh Aluri 3 Y Amy Siu 5 W George Lai 5 Sanae Yasuda 1 Jim Ferry 3 Bhaskar Rege 3
Affiliations

Affiliations

  • 1 Eisai Co., Ltd., Tokyo, Japan.
  • 2 Worldwide Clinical Trials, San Antonio, TX, USA.
  • 3 Eisai, Inc., Woodcliff Lake, NJ, USA.
  • 4 Eisai Ltd, Hatfield, UK.
  • 5 Eisai, Inc., Andover, MA, USA.
Abstract

Aims: Avatrombopag, a Thrombopoietin Receptor Agonist, is a substrate of Cytochrome P450 (CYP) 2C9 and CYP3A. We assessed three drug-drug interactions of avatrombopag as a victim with dual or selective CYP2C9/3A inhibitors and inducers.

Methods: This was a three-part, open-label study. Forty-eight healthy subjects received single 20 mg doses of avatrombopag alone or with one of 3 CYP2C9/3A inhibitors or inducers: fluconazole 400 mg once daily for 16 days, itraconazole 200 mg twice daily on Day 1 and 200 mg once daily on Days 2-16, or rifampicin 600 mg once daily for 16 days. Pharmacokinetics, pharmacodynamics (platelet count) and safety of avatrombopag were evaluated.

Results: Coadministration of a single 20-mg dose of avatrombopag with fluconazole at steady-state resulted in 2.16-fold increase of AUC of avatrombopag, prolonged terminal elimination phase half-life (from 19.7 h to 39.9 h) and led to a clinically significant increase in maximum platelet count (1.66-fold). Itraconazole had a mild increase on both avatrombopag pharmacokinetics and pharmacodynamics compared to fluconazole. Coadministration of rifampicin caused a 0.5-fold decrease in AUC and shortened terminal elimination phase half-life (from 20.3 h to 9.84 h), but has no impact on maximum platelet count. Coadministration with interacting drugs was found to be generally safe and well-tolerated.

Conclusions: The results from coadministration of fluconazole or itraconazole suggest that CYP2C9 plays a more predominant role in metabolic clearance of avatrombopag than CYP3A. To achieve comparable platelet count increases when avatrombopag is coadministered with CYP3A and CYP2C9 inhibitors, an adjustment in the dose or duration of treatment is recommended, while coadministration with strong inducers is not currently recommended.

Keywords

cytochrome; drug interactions; pharmacokinetics; physiologically based pharmacokinetics; platelet count.

Figures
Products